ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) formulation of DNAI1 mRNA was successfully and directly delivered to lungs as an inhaled aerosol with no significant exposure to other tissues ...
STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide ...
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia- obe-cel: poster presentation in ...
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2022, the Compensation Committee of its Board of Directors granted inducement ...
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in ...
New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika – an app-based DTx platform empowering people ...
ISELIN, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in ...
REGULATED INFORMATION Preliminary documents for the Annual and Extraordinary General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, 9 May 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and ...
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies ...
CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in ...
Copyright © 2015 - 2021 Lifecarenews.in
